Alexandra Legge1, Susan Kirkland1, Kenneth Rockwood1, Pantelis Andreou1, Sang-Cheol Bae2, Caroline Gordon3, Juanita Romero-Diaz4, Jorge Sanchez-Guerrero4, Daniel J Wallace5, Sasha Bernatsky6, Ann E Clarke7, Joan T Merrill8, Ellen M Ginzler9, Paul Fortin10, Dafna D Gladman11, Murray B Urowitz11, Ian N Bruce12, David A Isenberg13, Anisur Rahman13, Graciela S Alarcón14, Michelle Petri15, Munther A Khamashta16, M A Dooley17, Rosalind Ramsey-Goldman18, Susan Manzi19, Kristjan Steinsson20, Asad A Zoma21, Cynthia Aranow22, Meggan Mackay22, Guillermo Ruiz-Irastorza23, S Sam Lim24, Murat Inanc25, Ronald F van Vollenhoven26, Andreas Jonsen27, Ola Nived27, Manuel Ramos-Casals28, Diane L Kamen29, Kenneth C Kalunian30, Soren Jacobsen31, Christine A Peschken32, Anca Askanase33, John G Hanly34. 1. Dalhousie University, Halifax, Nova Scotia, Canada. 2. Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. 3. University of Birmingham, Birmingham, UK. 4. Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico. 5. Cedars-Sinai Medical Center and David Geffen School of Medicine at University of California, Los Angeles. 6. McGill University, Montreal, Quebec, Canada. 7. University of Calgary, Calgary, Alberta, Canada. 8. Oklahoma Medical Research Foundation, Oklahoma City. 9. SUNY Downstate Medical Center, Brooklyn, New York. 10. CHU de Québec et Université Laval, Quebec City, Canada. 11. Toronto Western Hospital and University of Toronto, Ontario, Canada. 12. University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK. 13. University College London, London, UK. 14. University of Alabama at Birmingham. 15. Johns Hopkins University School of Medicine, Baltimore, Maryland. 16. St Thomas' Hospital, King's College London School of Medicine, London, UK. 17. University of North Carolina, Chapel Hill. 18. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 19. Allegheny Health Network, Pittsburgh, Pennsylvania. 20. Landspitali University Hospital, Reykjavik, Iceland. 21. Hairmyres Hospital, East Kilbride, Scotland, UK. 22. Feinstein Institute for Medical Research, Manhasset, New York. 23. Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain. 24. Emory University School of Medicine, Atlanta, Georgia. 25. Istanbul University, Istanbul, Turkey. 26. Karolinska Institute, Stockholm, Sweden. 27. Lund University, Lund, Sweden. 28. Hospital Clínic de Barcelona, Barcelona, Spain. 29. Medical University of South Carolina, Charleston. 30. University of California San Diego School of Medicine, La Jolla. 31. Copenhagen University Hospital, Copenhagen, Denmark. 32. University of Manitoba, Winnipeg, Manitoba, Canada. 33. Hospital for Joint Diseases, New York University, New York. 34. Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
OBJECTIVE: To evaluate the properties of a frailty index (FI), constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, as a novel health measure in systemic lupus erythematosus (SLE). METHODS: For this secondary analysis, the baseline visit was defined as the first study visit at which both organ damage (SLICC/American College of Rheumatology Damage Index [SDI]) and health-related quality of life (Short-Form 36 [SF-36] scores) were assessed. The SLICC-FI was constructed using baseline data. The SLICC-FI comprises 48 health deficits, including items related to organ damage, disease activity, comorbidities, and functional status. Content, construct, and criterion validity of the SLICC-FI were assessed. Multivariable Cox regression was used to estimate the association between baseline SLICC-FI values and mortality risk, adjusting for demographic and clinical factors. RESULTS: In the baseline data set of 1,683 patients with SLE, 89% were female, the mean ± SD age was 35.7 ± 13.4 years, and the mean ± SD disease duration was 18.8 ± 15.7 months. At baseline, the mean ± SD SLICC-FI score was 0.17 ± 0.08 (range 0-0.51). Baseline SLICC-FI values exhibited the expected measurement properties and were weakly correlated with baseline SDI scores (r = 0.26, P < 0.0001). Higher baseline SLICC-FI values (per 0.05 increment) were associated with increased mortality risk (hazard ratio 1.59, 95% confidence interval 1.35-1.87), after adjusting for age, sex, steroid use, ethnicity/region, and baseline SDI scores. CONCLUSION: The SLICC-FI demonstrates internal validity as a health measure in SLE and might be used to predict future mortality risk. The SLICC-FI is potentially valuable for quantifying vulnerability among patients with SLE, and adds to existing prognostic scores.
OBJECTIVE: To evaluate the properties of a frailty index (FI), constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, as a novel health measure in systemic lupus erythematosus (SLE). METHODS: For this secondary analysis, the baseline visit was defined as the first study visit at which both organ damage (SLICC/American College of Rheumatology Damage Index [SDI]) and health-related quality of life (Short-Form 36 [SF-36] scores) were assessed. The SLICC-FI was constructed using baseline data. The SLICC-FI comprises 48 health deficits, including items related to organ damage, disease activity, comorbidities, and functional status. Content, construct, and criterion validity of the SLICC-FI were assessed. Multivariable Cox regression was used to estimate the association between baseline SLICC-FI values and mortality risk, adjusting for demographic and clinical factors. RESULTS: In the baseline data set of 1,683 patients with SLE, 89% were female, the mean ± SD age was 35.7 ± 13.4 years, and the mean ± SD disease duration was 18.8 ± 15.7 months. At baseline, the mean ± SD SLICC-FI score was 0.17 ± 0.08 (range 0-0.51). Baseline SLICC-FI values exhibited the expected measurement properties and were weakly correlated with baseline SDI scores (r = 0.26, P < 0.0001). Higher baseline SLICC-FI values (per 0.05 increment) were associated with increased mortality risk (hazard ratio 1.59, 95% confidence interval 1.35-1.87), after adjusting for age, sex, steroid use, ethnicity/region, and baseline SDI scores. CONCLUSION: The SLICC-FI demonstrates internal validity as a health measure in SLE and might be used to predict future mortality risk. The SLICC-FI is potentially valuable for quantifying vulnerability among patients with SLE, and adds to existing prognostic scores.
Authors: Kenneth Rockwood; Xiaowei Song; Chris MacKnight; Howard Bergman; David B Hogan; Ian McDowell; Arnold Mitnitski Journal: CMAJ Date: 2005-08-30 Impact factor: 8.262
Authors: David Aguirre-Valencia; Ana Suárez-Avellaneda; Vanessa Ocampo-Piraquive; Iván Posso-Osorio; Juan Naranjo-Escobar; Ivana Nieto-Aristizábal; Gabriel J Tobón; Carlos A Cañas Journal: Clin Rheumatol Date: 2019-04-15 Impact factor: 2.980
Authors: Kaitlin Lima; Alexandra Legge; John G Hanly; Jungwha Lee; Jing Song; Anh Chung; Rosalind Ramsey-Goldman Journal: Arthritis Care Res (Hoboken) Date: 2021-09-30 Impact factor: 4.794
Authors: Alexandra Legge; Susan Kirkland; Kenneth Rockwood; Pantelis Andreou; Sang-Cheol Bae; Caroline Gordon; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Daniel J Wallace; Sasha Bernatsky; Ann E Clarke; Joan T Merrill; Ellen M Ginzler; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; David A Isenberg; Anisur Rahman; Graciela S Alarcón; Michelle Petri; Munther A Khamashta; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Asad A Zoma; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Ronald F van Vollenhoven; Andreas Jonsen; Ola Nived; Manuel Ramos-Casals; Diane L Kamen; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Anca Askanase; John G Hanly Journal: Arthritis Rheumatol Date: 2020-02-12 Impact factor: 15.483
Authors: Gemma F Spiers; Tafadzwa Patience Kunonga; Alex Hall; Fiona Beyer; Elisabeth Boulton; Stuart Parker; Peter Bower; Dawn Craig; Chris Todd; Barbara Hanratty Journal: BMJ Open Date: 2021-03-22 Impact factor: 2.692
Authors: John G Hanly; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Andreas Jonsen; Graciela S Alarcón; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Vernon Farewell Journal: Arthritis Rheumatol Date: 2021-10-29 Impact factor: 15.483
Authors: Alexandra Legge; Susan Kirkland; Kenneth Rockwood; Pantelis Andreou; Sang-Cheol Bae; Caroline Gordon; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Daniel J Wallace; Sasha Bernatsky; Ann E Clarke; Joan T Merrill; Ellen M Ginzler; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; David A Isenberg; Anisur Rahman; Graciela S Alarcón; Michelle Petri; Munther A Khamashta; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Asad A Zoma; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Ronald F van Vollenhoven; Andreas Jonsen; Ola Nived; Manuel Ramos-Casals; Diane L Kamen; Kenneth C Kalunian; Søren Jacobsen; Christine A Peschken; Anca Askanase; John G Hanly Journal: Arthritis Care Res (Hoboken) Date: 2022-02-17 Impact factor: 5.178